Literature DB >> 23357351

Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance.

Lara Bellardita1, Tiziana Rancati, Maria Francesca Alvisi, Daniela Villani, Tiziana Magnani, Cristina Marenghi, Nicola Nicolai, Giuseppe Procopio, Sergio Villa, Roberto Salvioni, Riccardo Valdagni.   

Abstract

BACKGROUND: Active surveillance (AS) is emerging as an alternative approach to limit the risk of overtreatment and impairment of quality of life (QoL) in patients with low-risk localised prostate cancer. Although most patients report high levels of QoL, some men may be distressed by the idea of living with untreated cancer.
OBJECTIVE: To identify factors associated with poor QoL during AS. DESIGN, SETTING, AND PARTICIPANTS: Between September 2007 and March 2012, 103 patients participated in the Prostate Cancer Research International Active Surveillance (PRIAS) QoL study. Mental health (Symptom Checklist-90), demographic, clinical, and decisional data were assessed at entrance in AS. Health-related QoL (HRQoL) Functional Assessment of Cancer Therapy-Prostate version and Mini-Mental Adjustment to Cancer outcomes were assessed after 10 mo of AS. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariate logistic regression models were used to identify predictors of low (<25th percentile) HRQoL, adjustment to cancer, and a global QoL index at 10 mo after enrollment. RESULTS AND LIMITATIONS: The mean age of the study patients was 67 yr (standard deviation: ±7 yr). Lack of partner (odds ratio [OR]: 0.08; p=0.009) and impaired mental health (OR: 1.2, p=0.1) were associated with low HRQoL (p=0.006; area under the curve [AUC]: 0.72). The maladaptive adjustment to cancer (p=0.047; AUC: 0.60) could be predicted by recent diagnosis (OR: 3.3; p=0.072). Poor global QoL (overall p=0.02; AUC: 0.85) was predicted by impaired mental health (OR: 1.16; p=0.070) and time from diagnosis to enrollment in AS <5 mo (OR: 5.52; p=0.009). Influence of different physicians on the choice of AS (OR: 0.17; p=0.044), presence of a partner (OR: 0.22; p=0.065), and diagnostic biopsy with >18 core specimens (OR: 0.89; p=0.029) were predictors of better QoL. Limitations of this study were the small sample size and the lack of a control group.
CONCLUSIONS: Factors predicting poor QoL were lack of a partner, impaired mental health, recent diagnosis, influence of clinicians and lower number of core samples taken at diagnostic biopsy. Educational support from physicians and emotional/social support should be promoted in some cases to prevent poor QoL.
Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23357351     DOI: 10.1016/j.eururo.2013.01.009

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  21 in total

1.  How do prostate cancer patients navigate the active surveillance journey? A 3-year longitudinal study.

Authors:  Paola Dordoni; Fabio Badenchini; Maria Francesca Alvisi; Julia Menichetti; Letizia De Luca; Teresa Di Florio; Tiziana Magnani; Cristina Marenghi; Tiziana Rancati; Riccardo Valdagni; Lara Bellardita
Journal:  Support Care Cancer       Date:  2020-05-18       Impact factor: 3.603

Review 2.  Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer.

Authors:  Christopher J Welty; Matthew R Cooperberg; Peter R Carroll
Journal:  Curr Opin Urol       Date:  2014-05       Impact factor: 2.309

3.  Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer.

Authors:  Richard M Hoffman; Tania Lobo; Stephen K Van Den Eeden; Kimberly M Davis; George Luta; Amethyst D Leimpeter; David Aaronson; David F Penson; Kathryn Taylor
Journal:  Med Decis Making       Date:  2019-10-21       Impact factor: 2.583

4.  Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.

Authors:  Netty Kinsella; Pär Stattin; Declan Cahill; Christian Brown; Anna Bill-Axelson; Ola Bratt; Sigrid Carlsson; Mieke Van Hemelrijck
Journal:  Eur Urol       Date:  2018-03-26       Impact factor: 20.096

5.  The Relationships Between Spiritual Well-Being, Quality of Life, and Psychological Factors Before Radiotherapy for Prostate Cancer.

Authors:  Sara J Walker; Yiyi Chen; Kyungjeen Paik; Brandy Mirly; Charles R Thomas; Arthur Y Hung
Journal:  J Relig Health       Date:  2017-10

6.  The association of marital status and mortality among men with early-stage prostate cancer treated with radical prostatectomy: insight into post-prostatectomy survival strategies.

Authors:  Saira Khan; Kenneth G Nepple; Adam S Kibel; Gurdarshan Sandhu; Dorina Kallogjeri; Seth Strope; Robert Grubb; Kathleen Y Wolin; Siobhan Sutcliffe
Journal:  Cancer Causes Control       Date:  2019-06-18       Impact factor: 2.506

7.  Five-year nationwide follow-up study of active surveillance for prostate cancer.

Authors:  Stacy Loeb; Yasin Folkvaljon; Danil V Makarov; Ola Bratt; Anna Bill-Axelson; Pär Stattin
Journal:  Eur Urol       Date:  2014-06-30       Impact factor: 20.096

8.  A quantitative analysis of the prevalence of clinical depression and anxiety in patients with prostate cancer undergoing active surveillance.

Authors:  Sam Watts; Geraldine Leydon; Caroline Eyles; Caroline M Moore; Alison Richardson; Brian Birch; Philip Prescott; Catrin Powell; George Lewith
Journal:  BMJ Open       Date:  2015-05-22       Impact factor: 2.692

Review 9.  Patient and provider experiences with active surveillance: A scoping review.

Authors:  Claire Kim; Frances C Wright; Nicole J Look Hong; Gary Groot; Lucy Helyer; Pamela Meiers; May Lynn Quan; Robin Urquhart; Rebecca Warburton; Anna R Gagliardi
Journal:  PLoS One       Date:  2018-02-05       Impact factor: 3.240

10.  Deaths and major biographical events: a study of all cancer deaths in Germany from 1995 to 2009.

Authors:  Daniel Medenwald; Oliver Kuss
Journal:  BMJ Open       Date:  2014-04-02       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.